native med semaglutide | Personalized Weight Loss Medications The FDA Has Approved An
Description
What Research Shows About Semaglutide In the STEP-1 trial (published in the New England Journal of Medicine , 2021), adults with overweight or obesity who took 2.4 mg semaglutide weekly lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% in the placebo group
A group of scientists jumped on those anti-alcohol anecdotes and decided to see if the weight loss drug could also serve as a treatment for alcohol addiction
In their separate trials, the Wegovy pill averaged about 13.6% over 64 weeks and Foundayo about 11.2% over 72 weeks at the top dose
Instructions for completing the form
Rather than viewing semaglutide as a restriction, frame it as permission to enjoy favorite meals in smaller, more deliberate amounts
